Latest industry research report on: Global Hemoglobinopathies Market 2016: Industry Research, Size, Shares, Key Trends, Demand, Growth to 2022
Hemoglobinopathy is a genetic disorder that causes structural abnormalities in hemoglobin molecules, particularly defective globin chains. Hemoglobinopathies are inherited single-gene disorders of which sickle cell disease is the most common kind. There is a high prevalence of Hemoglobinopathies in Africa, Southeast Asia and the Mediterranean basin. If left untreated, critical cases of hemoglobinopathies lead to anemia, organ dysfunction or death. Gel electrophoresis and complete blood count are used as diagnostic tests to determine the presence of hemoglobinopathies.
The disease does not have a permanent cure; this has resulted in a growing demand for new product innovations in the pharmaceutical sector. Additionally, the high prevalence of the disease and the national control program are driving the need for drug therapy in developing economies. Alnylam Pharmaceuticals, Gamilda Cell, Sangamo Biosciences, Cancer Therapeutics CRC Pty Ltd and Biogen Idec are some of the key players in this market. These companies have invested huge sums of money in research and development of hemoglobinopathies to develop a permanent cure for this disease. NiCord, ZFP and ALN-TMP are some of the current products available in the market. Companies have adopted the strategy of collaboration and licensing to supplement their research activities.
Get Free Sample Report Of Hemoglobinopathies Market :http://www.custommarketinsights.com/world-hemoglobinopathies-market-/102838#cs_tabs_request_for_sample
Global hemoglobinopathies market is segmented on the basis therapeutics and geography. The therapeutic segment includes various drugs such as NiCord, ZFP Transcription Factors, ALN-TMP, Drug Targeting PRMT5 and Drug Targeting Protein Arginine Methyltransferase 5. ALN-TMP is a subcutaneous RNAi therapeutic that targets Tmprss6 and is used in the treatment of ?-thalassemia. NiCord®, based on the novel NAM technology, is a potential solution for a number of diseases such as thalassemia, sickle cell disease, hematological malignancies, severe rare genetic metabolic diseases and autoimmune diseases. Geographically, the global hemoglobinopathies market is segmented into North America, Europe, Asia-Pacific and LAMEA. Africa is the leading market for these drugs due to the high prevalence of hemoglobinopathies in the region.
Have Any Query? Ask Our Expert @http://www.custommarketinsights.com/world-hemoglobinopathies-market-/102838#cs_tabs_enquiry_for_buying
KEY MARKET SEGMENTS
The global hemoglobinopathies market is segmented into two major categories: pipeline therapeutics and geography.
MARKET BY PIPELINE THERAPEUTICS
MARKET BY GEOGRAPHY
About Custom Market Insights:
Market Research supports various market segment programs; provides trusted technical services to the marketing departments. It carries out accurate market share and forecast analysis services for a range of commercial and government customers globally. These are all vital market research support solutions requiring trust and integrity.
Custom Market Insights is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive.
What makes us different from our competitors?
Compared to our competitors, our offerings include, but are not limited to market research services on latest industry trends, customized study at reasonable price, and database bigger than our competitors and provide more relevant results to fit your needs.
3422 SW 15 Street, Suit #8138,
Deerfield Beach, Florida 33442,
GMT Tel: +49-322 210 92714
USA/Canada Toll Free No. 1-855-465-4651